5578

543349

ACUTAAS

img img img img
No Data Available

ACUTAAS CHEMICALS LIMITED Share Price Update

As of the latest trading session, ACUTAAS CHEMICALS LIMITED is trading at ₹2923.8, down by ₹-27.39 or -0.92% from its previous close. The stock has moved between ₹2864.20 and ₹2963.30 today. Over the past year, the stock has delivered a return of 148.29%. In the last month, it has returned 21.78%.

ACUTAAS CHEMICALS LIMITED performance

Today’s low Today’s high
₹ 2864.20 ₹ 2963.30
₹ 2923.80
52 week low 52 week high
₹ 1059.00 ₹ 3025.00
₹ 2923.80
Open Price ₹ 2920.00
Prev. Close ₹ 2951.20
Volume (Shares) 333964.00
Total traded value ₹ 9764.43
Upper Circuit ₹ 3541.40
Lower Circuit ₹ 2361.00
info

Investment Returns

Over 1 Month 21.78% Over 3 Months 37.46% Over 6 Months 57.63% Over 1 Year 148.29%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ACUTAAS CHEMICALS LIMITED fundamentals


  • Market cap (Cr) 23,937.50
  • P/E Ratio (TTM) 65.92
  • Beta 1.11
  • Book Value / share 203.78
  • Return on equity 16.06%
  • EPS (TTM) 44.73
  • Dividend yield 0.08%
  • Net profit/quarter (Cr) 137.07
info icon alternate text
  • Market cap (Cr) 23,963.70
  • P/E Ratio (TTM) 65.92
  • Beta 1.00
  • Book Value / share 203.78
  • Return on equity 16.06%
  • EPS (TTM) 44.73
  • Dividend yield 0.08%
  • Net profit/quarter (Cr) 137.07
info icon alternate text

ACUTAAS CHEMICALS LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 421.77
Operating Expense 250.45
Net Profit 137.07
Net Profit Margin (%) 32.49
Earnings Per Share (EPS) 16.74
EBITDA 195.76
Effective Tax Rate (%) 26.25
Particulars DEC 2025 (Values in Cr)
Revenue 390.86
Operating Expense 246.49
Net Profit 111.57
Net Profit Margin (%) 28.54
Earnings Per Share (EPS) 13.63
EBITDA 160.53
Effective Tax Rate (%) 25.97
Particulars SEP 2025 (Values in Cr)
Revenue 305.19
Operating Expense 216.88
Net Profit 72.89
Net Profit Margin (%) 23.88
Earnings Per Share (EPS) 8.90
EBITDA 105.57
Effective Tax Rate (%) 25.07
Particulars JUN 2025 (Values in Cr)
Revenue 205.97
Operating Expense 163.06
Net Profit 44.65
Net Profit Margin (%) 21.67
Earnings Per Share (EPS) 5.45
EBITDA 67.00
Effective Tax Rate (%) 24.23
Particulars MAR 2025 (Values in Cr)
Revenue 304.16
Operating Expense 227.04
Net Profit 62.85
Net Profit Margin (%) 20.66
Earnings Per Share (EPS) 7.84
EBITDA 89.75
Effective Tax Rate (%) 24.11
Particulars MAR 2026 (Values in Cr)
Revenue 1323.79
Operating Expense 876.90
Net Profit 366.17
Net Profit Margin (%) 27.66
Earnings Per Share (EPS) 44.73
EBITDA 528.88
Effective Tax Rate (%) 25.69
Particulars MAR 2025 (Values in Cr)
Revenue 989.83
Operating Expense 794.60
Net Profit 159.55
Net Profit Margin (%) 16.11
Earnings Per Share (EPS) 19.91
EBITDA 243.49
Effective Tax Rate (%) 25.29
Particulars MAR 2024 (Values in Cr)
Revenue 687.58
Operating Expense 600.50
Net Profit 43.68
Net Profit Margin (%) 6.35
Earnings Per Share (EPS) 11.91
EBITDA 89.69
Effective Tax Rate (%) 36.78
Particulars MAR 2023 (Values in Cr)
Revenue 616.73
Operating Expense 508.82
Net Profit 83.34
Net Profit Margin (%) 13.51
Earnings Per Share (EPS) 22.87
EBITDA 126.97
Effective Tax Rate (%) 25.73
Particulars MAR 2022 (Values in Cr)
Revenue 520.14
Operating Expense 431.45
Net Profit 71.95
Net Profit Margin (%) 13.83
Earnings Per Share (EPS) 21.03
EBITDA 107.94
Effective Tax Rate (%) 21.32
Particulars MAR 2025 (Values in Cr)
Book Value / Share 159.97
ROE % 16.17
ROCE % 20.06
Total Debt to Total Equity 0.12
EBITDA Margin 24.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 182.75
ROE % 10.67
ROCE % 16.07
Total Debt to Total Equity 0.17
EBITDA Margin 18.92
Particulars MAR 2023 (Values in Cr)
Book Value / Share 163.01
ROE % 14.92
ROCE % 20.43
Total Debt to Total Equity 0.00
EBITDA Margin 20.58
Particulars MAR 2022 (Values in Cr)
Book Value / Share 143.34
ROE % 20.88
ROCE % 23.54
Total Debt to Total Equity 0.20
EBITDA Margin 20.75
Particulars MAR 2021 (Values in Cr)
Book Value / Share 52.99
ROE % 38.75
ROCE % 32.12
Total Debt to Total Equity 0.70
EBITDA Margin 23.94
Particulars MAR 2025 (Values in Cr)
Book Value / Share 160.21
ROE % 16.06
ROCE % 19.91
Total Debt to Total Equity 0.11
EBITDA Margin 24.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 183.05
ROE % 9.36
ROCE % 13.51
Total Debt to Total Equity 0.16
EBITDA Margin 16.58
Particulars MAR 2023 (Values in Cr)
Book Value / Share 161.04
ROE % 15.09
ROCE % 20.65
Total Debt to Total Equity 0.00
EBITDA Margin 20.59
Particulars MAR 2022 (Values in Cr)
Book Value / Share 142.16
ROE % 21.10
ROCE % 23.75
Total Debt to Total Equity 0.20
EBITDA Margin 20.75
Particulars MAR 2021 (Values in Cr)
Book Value / Share 52.05
ROE % 39.72
ROCE % 32.58
Total Debt to Total Equity 0.72
EBITDA Margin 23.94
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 248.92
Total Assets 1549.26
Total Liabilities 1549.26
Total Equity 1320.08
Share Outstanding 8
Price to Book Ratio 15.24
Return on Assets (%) 10.24
Return on Capital (%) 11.95
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 53.31
Total Assets 1095.90
Total Liabilities 1095.90
Total Equity 682.75
Share Outstanding 3
Price to Book Ratio 5.98
Return on Assets (%) 3.90
Return on Capital (%) 4.76
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.67
Total Assets 766.93
Total Liabilities 766.93
Total Equity 593.95
Share Outstanding 3
Price to Book Ratio 5.52
Return on Assets (%) 10.86
Return on Capital (%) 13.94
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 99.55
Total Assets 658.88
Total Liabilities 658.88
Total Equity 522.27
Share Outstanding 3
Price to Book Ratio 7.03
Return on Assets (%) 10.91
Return on Capital (%) 13.75
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.68
Total Assets 413.26
Total Liabilities 413.26
Total Equity 166.93
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 13.06
Return on Capital (%) 17.79
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 240.72
Total Assets 1537.95
Total Liabilities 1537.95
Total Equity 1311.59
Share Outstanding 8
Price to Book Ratio 15.24
Return on Assets (%) 10.37
Return on Capital (%) 12.11
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 31.94
Total Assets 1071.25
Total Liabilities 1071.25
Total Equity 675.11
Share Outstanding 3
Price to Book Ratio 5.98
Return on Assets (%) 4.07
Return on Capital (%) 4.98
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.61
Total Assets 759.46
Total Liabilities 759.46
Total Equity 586.78
Share Outstanding 3
Price to Book Ratio 5.52
Return on Assets (%) 10.97
Return on Capital (%) 14.12
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 98.91
Total Assets 654.60
Total Liabilities 654.60
Total Equity 518.00
Share Outstanding 3
Price to Book Ratio 7.03
Return on Assets (%) 10.99
Return on Capital (%) 13.87
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.55
Total Assets 410.28
Total Liabilities 410.28
Total Equity 163.95
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 13.16
Return on Capital (%) 19.21
Particulars MAR 2025 (Values in Cr)
Net Income 216.16
Cash from Operations 165.08
Cash from Investing -223.94
Cash from Financing 261.12
Net change in Cash 155.51
Free Cash Flow 359.72
Particulars MAR 2024 (Values in Cr)
Net Income 81.90
Cash from Operations 149.51
Cash from Investing -365.39
Cash from Financing 239.36
Net change in Cash -0.86
Free Cash Flow 464.19
Particulars MAR 2023 (Values in Cr)
Net Income 112.17
Cash from Operations 89.98
Cash from Investing -33.04
Cash from Financing -12.25
Net change in Cash 20.23
Free Cash Flow 168.33
Particulars MAR 2022 (Values in Cr)
Net Income 91.45
Cash from Operations 10.87
Cash from Investing -120.71
Cash from Financing 140.26
Net change in Cash 7.61
Free Cash Flow 44.63
Particulars MAR 2021 (Values in Cr)
Net Income 71.72
Cash from Operations 42.13
Cash from Investing -101.20
Cash from Financing 72.10
Net change in Cash -1.13
Free Cash Flow 149.25
Particulars MAR 2025 (Values in Cr)
Net Income 213.57
Cash from Operations 159.64
Cash from Investing -234.37
Cash from Financing 273.56
Net change in Cash 155.11
Free Cash Flow 350.65
Particulars MAR 2024 (Values in Cr)
Net Income 69.10
Cash from Operations 116.96
Cash from Investing -337.35
Cash from Financing 235.48
Net change in Cash -1.02
Free Cash Flow 422.47
Particulars MAR 2023 (Values in Cr)
Net Income 112.22
Cash from Operations 80.18
Cash from Investing -20.47
Cash from Financing -14.43
Net change in Cash 20.81
Free Cash Flow 145.85
Particulars MAR 2022 (Values in Cr)
Net Income 91.45
Cash from Operations 13.12
Cash from Investing -122.46
Cash from Financing 140.26
Net change in Cash 8.10
Free Cash Flow 45.91
Particulars MAR 2021 (Values in Cr)
Net Income 71.72
Cash from Operations 40.55
Cash from Investing -100.20
Cash from Financing 72.10
Net change in Cash -1.71
Free Cash Flow 144.44
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 13.67 1.60 253.43 23.12 40.00
BLISS GVS PHARMA LTD. 300.20 24.29 2.66 3175.78 118.35 304.30
CIPLA LTD. 1398.95 27.70 3.28 113007.26 1165.55 1672.20
FERMENTA BIOTECH LIMITED 302.65 10.07 2.27 890.73 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 23.13 4.26 253.43 23.12 40.00
AMRUTAJAN HEALTH LTD 558.20 25.02 4.35 1613.79 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8604.25 103.40 26.92 21510.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 300.20 32.28 2.74 3175.78 118.35 304.30

ACUTAAS CHEMICALS LIMITED shareholding pattern

Holding
28.25%
32.66%
19.48%
19.6%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

ACUTAAS CHEMICALS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2923.80 -0.92 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2907.10
  • 26 Days 2678.30
  • 10 Days 2841.30
  • 50 Days 2510.30
  • 12 Days 2817.30
  • 100 Days 2268.40
  • 20 Days 2731.70
  • 200 Days 1956.30
2960.73 PIVOT
First Support 2920.47 First Resistance 2991.47 Second Support 2889.73 Second Resistance 3031.73 Third Support 2849.47 Third Resistance 3062.47
RSI 68.25 ADX 68.67 MACD 138.95 Williams % R -17.55 Commodity Channel Index (CCI) 134.68
Date 2026-05-22 Week 215105.00 Same Day 153530.00 Month 249695.00
1 Year 1.12 3 Year 1.14
Over 1 Month
21.78% down
Over 1 Year
148.29% down
Over 3 Months
37.46% down
Over 3 Years
70.99% down
Over 6 Months
57.63% down
Over 5 Years
44.55% down

ACUTAAS CHEMICALS LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2025 1.5 Final 18 Sep 2025 Equity shares
13 Sep 2024 3.0 Final 13 Sep 2024 Equity shares
18 Sep 2023 3.0 Final 18 Sep 2023 Equity shares
29 Jul 2022 3.0 Final 01 Aug 2022 Equity shares
Ex-Date Old FV NEW FV Record Date
25 Apr 2025 10.0 5.0 25 Apr 2025
Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2025 1.5 Final 18 Sep 2025 Equity shares
13 Sep 2024 3.0 Final 13 Sep 2024 Equity shares
18 Sep 2023 3.0 Final 18 Sep 2023 Equity shares
29 Jul 2022 3.0 Final 01 Aug 2022 Equity shares
Ex-Date Old FV NEW FV Record Date
25 Apr 2025 10.0 5.0 25 Apr 2025

Top Gainers

Top Losers

ACUTAAS CHEMICALS LIMITED Share Price

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India. The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007. Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018. The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies.

The Company is engaged in business of drugs intermediate chemicals and related activities. The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. The Company Implemented the Integrated Management System (IMS) in 2011; it incorporated Ami OncoTheranostics, LLC in Delware, USA along with Photolitec LLC as a 50-50 JV in 2015. It increased warehouse capacity, equipped with modern infrastructure & a storage capacity of 1,050 MT of RM in 2017.

The Company commenced its new Solvent Recovery Plant at Sachin in 2020. It acquired two units namely, the Ankleshwar and Jhagadia units from Gujarat Organics Limited (GOL) in 2021.

The Company came out with an IPO which comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholders, mopped up with a total of Rs 570 crore through its public issue in September, 2021.

The Company incorporated wholly owned subsidiary Ami Organics Electrolytes Private Limited in 2023. The Company further embarked on setting brownfield project at Ankleshwar entailing a capex of Rs. 1900 Million. The existing Ankleshwar facility was demolished and work started to set up a new plant with advance technology for pharma intermediates business, scheduled to have installed capacity of 436.5 KL.

The Company acquired a 55% stake in Baba Fine Chemicals (BFC) in FY 2024.

The state-of-the-art technology driven plant in Ankleshwar Unit with the total reactor capacity of 442 KL for the manufacture of advanced pharmaceutical intermediate business with Distributed Control System (DCS) technology is made fully operational in FY 2025.

Parent organization Indian Private
NSE symbol ACUTAAS
Founded 2007
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Acutaas Chemicals Ltd?

Answer Field

Acutaas Chemicals Ltd share price is for NSE ₹ 2,923.80 & for BSE ₹ 2,927.00 as on May 25 2026 03:30 PM.

What is the Market Cap of Acutaas Chemicals Ltd Share?

Answer Field

The market cap of Acutaas Chemicals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 25 2026 03:30 PM.

What is the 52 Week High and Low of Acutaas Chemicals Ltd?

Answer Field

The 52 Week High and Low of Acutaas Chemicals Ltd for NSE is ₹ 3,025.00 and ₹ 1,059.00 and for BSE is ₹ 3,024.45 and ₹ 1,059.05.

What is 1 year return for Acutaas Chemicals Ltd?

Answer Field

The 1 year returns on the stock has been 148.29%.

What is the P/E Ratio of Acutaas Chemicals Ltd Share?

Answer Field

As on May 25 2026 03:30 PM the price-to-earnings (PE) ratio for Acutaas Chemicals Ltd share is 65.92.

What is the PB ratio of Acutaas Chemicals Ltd Share?

Answer Field

As on May 25 2026 03:30 PM, the price-to-book (PB) ratio for Acutaas Chemicals Ltd share is 203.78.

How to Buy Acutaas Chemicals Ltd Share?

Answer Field

You can trade in Acutaas Chemicals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Acutaas Chemicals Ltd Share on Bajaj Broking App?

Answer Field

To buy Acutaas Chemicals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Acutaas Chemicals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|